Predictive probability of success and the assessment of futility in large outcomes trials

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 1, 2007, Pages 45-63

  Trzaskoma, Benjamin ^a   Sashegyi, Andreas ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Binary data; Futility rules; Overdispersion; Predictive probability; Prior distribution

Indexed keywords

ARTICLE; BAYES THEOREM; DISPERSION; EXPOSURE; HUMAN; MATHEMATICAL MODEL; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RESPONSE VARIABLE; SAMPLE SIZE; TREATMENT OUTCOME;

ALGORITHMS; ANTI-INFECTIVE AGENTS; BAYES THEOREM; CLINICAL TRIALS DATA MONITORING COMMITTEES; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIALS; HUMANS; MEDICAL FUTILITY; PROBABILITY; PROTEIN C; RECOMBINANT PROTEINS; RESEARCH DESIGN; SAMPLE SIZE; SEPSIS; SOFTWARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845757107     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400601001485     Document Type: Article

References (21)

1. Abraham, E., Laterre, P. F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B., Francois, B., Guy, J. S., Brueckmann, M., Rea-Neto, A., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B., Macias, W for the ADDRESS Study Group. (2005). Drotrecogin alfa (activated) in adult severe sepsis patients at low risk of death. New England Journal of Medicine 353:1332-1341.
2. Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M., Wenger, N. for the RUTH Trial Investigators. (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New England Journal of Medicine 355:125-137.
3. Bernard, G. R., Vincent, J. L., Laterre, P. F., LaRosa, S. P., Dhainaut, J. F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., Fisher, C. J. (2001). Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 344:699-709.
4. Casella, G., George, E. I. (1992). Explaining the gibbs sampler. The American Statistician 46:167-174.
5. Choi, S. C., Smith, P. J., Becker, D. P. (1985). Early decision in clinical trials when the treatment differences are small. Control Clin. Trials 6:280-288.
6. Davison, A. C., Hinkley, D. V. (1997). Bootstrap Methods and Their Application. Cambridge: Cambridge University Press.
7. Freidlin, B., Korn, E. L. (2002). A comment on futility monitoring. Control Clin. Trials 23:355-36.
8. Gelman, A., Carlin, J. B., Stern, H. S., Rubin, D. B. (1995). Bayesian Data Analysis. Boca Raton: Chapman & Hall.
9. Halm, E. A., Lee, C., Chassin, M. R. (2002). Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Annals of Internal Medicine 137:511-520.
10. Halperin, M., Lan, K. K. G., Ware, J. H., Johnson, N. J., DeMets, D. L. (1982). An aid to monitoring in long-term clinical trials. Control Clin. Trials 3:311-323.
11. Herson, J. (1979). Predictive probability early termination plans for phase II clinical trials. Biometrics 35:775-783.
12. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., for the HERS Research Group. (1988). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280:605-613.
13. Jennison, C. J., Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall/CRC.
14. Johns, D., Andersen, J. S. (1999). Use of predictive probabilities in phase II and phase III clinical trials. J. Biopharm. Stat. 9(1):67-79.
15. Katzan, I. L., Furlan, A. J., Lloyd, L. E., Frank, J. I., Harper, D. L., Hinchey, J. A., Hammel, J. P., Qu, A., Sila, C. A. (2000). Use of tissue-type plasminogen activator for acute ischemic stroke. Journal of the American Medical Association 283:1151-1158.
16. Montori, V. M., Devereaux, P. J., Adhikari N. K. J. et al. (2005). Randomized trials stopped early for benefit. Journal of the American Medical Association 294(17):2203-2209.
17. Sashegyi, A. (2004). Too much success, much too soon? Good Clinical Practice Journal 11(10):8-9.
18. Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical trials: conditional or predictive power. Controlled Clinical Trials 7:8-17.
19. Van der Tweel, I., van Noord, P. A. H. (2003). Early stopping in clinical trials and epidemiologic studies for "futility": Conditional power versus sequential analysis. Journal of Clinical Epidemiology 56:610-617.
20. Wittes, J. (2000). Data safety monitoring boards: a brief introduction. Biopharmaceutical Report 8(1):1-7.
21. Women's Health Initiative Investigators' Writing Group. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association 288:321-333.